Development of a Selective and Potent PRMT4 PROTAC Degrader with Efficacy against Multiple Myeloma in Vitro and in Vivo
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.5c01022 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Yong Ju und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Fudan University, Laboratory of Smart Drug Delivery, MOE, Shanghai 201203, China. Hauptthemen laut MEDLINE: Multiple Myeloma, Protein-Arginine N-Methyltransferases, Antineoplastic Agents, Enzyme Inhibitors. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Protein arginine methyltransferase 4 (PRMT4) is highly expressed in relapsed or refractory multiple myeloma (MM) and is associated with poor prognosis. Conventional PRMT4 inhibitors face challenges including inadequate efficacy, acquired resistance, and inability to inhibit nonenzymatic functions. In this study, we developed a proteolysis targeting chimera (PROTAC) targeting PRMT4, named C199, which is composed of the PRMT4 inhibitor EZM2302, a linker, and a von Hippel-Lindau (VHL) E3 ligase ligand. C199 demonstrated potent cellular degradation (DC50 = 106 nM, Dmax = 93.1%) and showed high selectivity for PRMT4 over other protein arginine methyltransferases. Importantly, in vivo studies showed that C199 had a relatively long half-life (10.10 h versus 4.89 h for EZM2302) and demonstrated strong antitumor activity (TGI = 78% versus 49% for EZM2302) without significant toxicity even at high doses. These findings provide the first evidence that PRMT4-targeted PROTAC degrader can exhibit therapeutic effects in vivo, offering a promising new therapeutic strategy for MM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, Fudan University, Laboratory of Smart Drug Delivery, MOE, Shanghai 201203, China.
ORCID-Profile: Jianzhong Lu
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Ju, Y., Song, H., He, Y., Lo, Y., Fan, Z., & Lu, J. (2025). Development of a Selective and Potent PRMT4 PROTAC Degrader with Efficacy against Multiple Myeloma in Vitro and in Vivo. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c01022
Vancouver
Ju Y, Song H, He Y, Lo Y, Fan Z, Lu J. Development of a Selective and Potent PRMT4 PROTAC Degrader with Efficacy against Multiple Myeloma in Vitro and in Vivo. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c01022
BibTeX
@article{Ju2025,
author = {Ju, Yong and Song, Huizhu and He, Yuelan and Lo, Yingtung and Fan, Zhipeng and Lu, Jianzhong},
title = {Development of a Selective and Potent PRMT4 PROTAC Degrader with Efficacy against Multiple Myeloma in Vitro and in Vivo},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.5c01022}
}
EUVIMED